Published in Antimicrob Agents Chemother on July 01, 2003
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother (2007) 2.58
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother (2006) 2.35
Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother (2009) 2.15
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother (2006) 2.14
Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2004) 1.99
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother (2010) 1.95
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med (2006) 1.90
Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis (2004) 1.89
An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother (2010) 1.71
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother (2012) 1.63
The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis (2012) 1.61
Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis (2010) 1.52
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother (2008) 1.50
The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother (2011) 1.49
Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother (2009) 1.47
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother (2010) 1.45
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother (2013) 1.44
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother (2014) 1.41
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother (2007) 1.34
Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2006) 1.33
Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.29
Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One (2011) 1.20
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med (2008) 1.19
Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother (2013) 1.18
Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin Microbiol Infect Dis (2008) 1.15
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol (2011) 1.15
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother (2008) 1.14
Current development and future prospects in chemotherapy of tuberculosis. Respirology (2010) 1.12
Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob Agents Chemother (2010) 1.08
Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08
Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog (2012) 1.06
Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother (2010) 1.04
Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS (2013) 1.04
Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother (2012) 1.02
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. Antimicrob Agents Chemother (2009) 1.02
Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob Agents Chemother (2013) 1.02
Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. Antimicrob Agents Chemother (2014) 1.01
Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother (2011) 0.99
Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice. EMBO Mol Med (2011) 0.99
Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob Agents Chemother (2006) 0.99
Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model. PLoS One (2014) 0.98
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother (2012) 0.98
High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front Microbiol (2015) 0.95
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrob Agents Chemother (2012) 0.93
Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother (2014) 0.92
Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy (2009) 0.92
Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev (2013) 0.91
Assessment of the Efficacy of New Anti-Tuberculosis Drugs. Open Infect Dis J (2008) 0.91
A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment. J Theor Biol (2014) 0.87
Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis. Antimicrob Agents Chemother (2013) 0.87
Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response. Antimicrob Agents Chemother (2014) 0.87
A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob Agents Chemother (2013) 0.86
In silico evaluation and exploration of antibiotic tuberculosis treatment regimens. BMC Syst Biol (2015) 0.86
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One (2014) 0.86
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother (2014) 0.85
Contradictory results with high-dosage rifamycin in mice and humans. Antimicrob Agents Chemother (2013) 0.84
In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Med Chem (2010) 0.84
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC Pharmacol Toxicol (2014) 0.83
Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis. PLoS One (2014) 0.83
Breakpoints and drug exposure are inevitably closely linked. Antimicrob Agents Chemother (2015) 0.82
Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging. Antimicrob Agents Chemother (2015) 0.82
Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmgenomics Pers Med (2012) 0.82
Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol (2014) 0.82
A multi-scale approach to designing therapeutics for tuberculosis. Integr Biol (Camb) (2015) 0.82
Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis (2013) 0.81
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother (2015) 0.80
Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. Antimicrob Agents Chemother (2015) 0.80
Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Pharmacotherapy (2014) 0.80
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Eur J Clin Pharmacol (2016) 0.80
Aerosol infection model of tuberculosis in wistar rats. Int J Microbiol (2010) 0.79
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. Antimicrob Agents Chemother (2015) 0.79
Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. Antimicrob Agents Chemother (2015) 0.79
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis (2016) 0.79
Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis. Surv Ophthalmol (2016) 0.79
A high-throughput cidality screen for Mycobacterium tuberculosis. PLoS One (2015) 0.79
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis (2016) 0.79
Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model. J Pharmacokinet Pharmacodyn (2015) 0.78
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One (2016) 0.78
New drugs to treat tuberculosis. F1000 Med Rep (2012) 0.78
Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin? Front Microbiol (2015) 0.77
Repurposing clinically approved cephalosporins for tuberculosis therapy. Sci Rep (2016) 0.77
Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection. Antimicrob Agents Chemother (2014) 0.76
Unravelling the Secrets of Mycobacterial Cidality through the Lens of Antisense. PLoS One (2016) 0.75
A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of Action. Antimicrob Agents Chemother (2016) 0.75
Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. Antimicrob Agents Chemother (2015) 0.75
Reply to "breakpoints and drug exposure are inevitably closely linked". Antimicrob Agents Chemother (2015) 0.75
Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa. Antimicrob Agents Chemother (2015) 0.75
Mycobacterium tuberculosis exploits the PPM1A signaling pathway to block host macrophage apoptosis. Sci Rep (2017) 0.75
Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infection. PLoS One (2017) 0.75
Reply to "Contradictory results with high-dosage rifamycin in mice and humans". Antimicrob Agents Chemother (2013) 0.75
Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment. J Pharmacokinet Pharmacodyn (2014) 0.75
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. Clin Infect Dis (2017) 0.75
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Pharmacokinetic evidence to support increased doses of rifampin for tuberculosis: results from the HIRIF trial. Antimicrob Agents Chemother (2017) 0.75
Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA (1999) 27.82
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (1998) 10.78
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet (1982) 6.06
In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother (1998) 4.88
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis (1989) 4.79
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother (1992) 3.72
The pharmacodynamics of beta-lactams. Clin Infect Dis (1998) 3.54
Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis (2000) 2.94
Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother (1999) 2.82
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet (2001) 2.68
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet (1995) 2.66
Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs. Am Rev Respir Dis (1970) 2.65
Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 2.43
Does the dose matter? Clin Infect Dis (2001) 2.38
Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect Immun (2000) 1.90
Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis (1992) 1.56
A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment. Tubercle (1991) 1.49
Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother (2002) 1.46
Pharmacodynamics of fluoroquinolones. Clin Infect Dis (1998) 1.42
Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis (1998) 1.34
In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle (1987) 1.30
Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. Antimicrob Agents Chemother (1998) 1.29
Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.25
The pharmacodynamics of aminoglycosides. Clin Infect Dis (1998) 1.18
The penetration of rifampicin, pyrazinamide, and pyrazinoic acid into mouse macrophages. Am Rev Respir Dis (1985) 1.14
Pharmacological issues in the treatment of tuberculosis. Ann N Y Acad Sci (2001) 1.14
Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol. Tubercle (1976) 1.10
The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Am J Med Sci (1997) 1.06
Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol (2001) 1.04
The combination of rifampicin and other antituberculous agents in chronic murine tuberculosis. Chemotherapy (1971) 0.99
Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria. J Antimicrob Chemother (2000) 0.98
Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin. Am Rev Respir Dis (1973) 0.87
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 11.22
An integrated map of the genome of the tubercle bacillus, Mycobacterium tuberculosis H37Rv, and comparison with Mycobacterium leprae. Proc Natl Acad Sci U S A (1996) 3.78
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science (2009) 3.39
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother (2006) 2.14
Prevalence of overweight and obesity in affluent adolescent girls in Chennai in 1981 and 1998. Indian Pediatr (2003) 2.05
Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2004) 1.99
A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment. Tubercle (1991) 1.49
Ambulatory ST segment monitoring. Problems, pitfalls, solutions, and clinical application. Br Heart J (1980) 1.39
Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci U S A (1981) 1.38
Effect of once-daily atenolol on ambulatory blood pressure. Br Med J (1979) 1.22
BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuber Lung Dis (1993) 1.20
Use of graded exercise testing in assessing the hypertensive patient. Clin Cardiol (1980) 1.18
Once daily beta-adrenoceptor blockade in hypertension: an ambulatory assessment. Br J Clin Pharmacol (1981) 1.16
Immunity to tuberculosis from the perspective of pathogenesis. Infect Immun (1989) 1.12
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 1.10
Exercise-induced ST segment elevation. Electrocardiographic, angiographic, and scintigraphic evaluation. Br Heart J (1980) 1.08
Propranolol LA and ambulatory blood pressure. Br J Clin Pharmacol (1980) 1.07
Myocardial ischaemia in patients with frequent angina pectoris. Br Med J (1979) 1.05
An analysis of some hypotheses related to the Chingelput bacille Calmette-Guérin trial. Clin Infect Dis (2000) 1.04
Ambulant blood pressure: reproducibility and the assessment of interventions. Clin Sci (Lond) (1980) 1.03
Verapamil in ischaemic heart disease--quantitative assessment by serial multistage treadmill exercise. Postgrad Med J (1976) 0.99
Molecular Characterization of Geographically Different Banana bunchy top virus Isolates in India. Indian J Virol (2011) 0.97
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J Med Chem (2013) 0.97
Aminonaphthoquinones--a novel class of compounds with potent antimalarial activity against Plasmodium falciparum. Pharmacol Res (2001) 0.93
Slow channel inhibitors verapamil and nifedipine in the management of hypertension. J Cardiovasc Pharmacol (1982) 0.93
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. J Med Chem (2014) 0.93
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrob Agents Chemother (2012) 0.93
Inactivation of the ilvB1 gene in Mycobacterium tuberculosis leads to branched-chain amino acid auxotrophy and attenuation of virulence in mice. Microbiology (2009) 0.91
High-throughput screen for inhibitors of transglycosylase and/or transpeptidase activities of Escherichia coli penicillin binding protein 1b. Antimicrob Agents Chemother (2004) 0.91
The toxicology of mercury and its compounds. J Trace Elem Med Biol (2012) 0.90
Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. J Med Chem (2014) 0.89
Animal models for experimental tuberculosis. Clin Infect Dis (2000) 0.89
Polyphosphate kinase from M. tuberculosis: an interconnect between the genetic and biochemical role. PLoS One (2010) 0.89
Effect of labetalol on continuous ambulatory blood pressure. Br J Clin Pharmacol (1979) 0.89
Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis. Antimicrob Agents Chemother (2013) 0.87
Blood pressure circadian rhythm in essential hypertension. Clin Sci Mol Med Suppl (1978) 0.87
Sudden death during ambulatory monitoring. Br Med J (1979) 0.87
Electrical impedance cardiogram in derivation of systolic time intervals. Br Heart J (1978) 0.87
Posterior epistaxis: identification of common bleeding sites. Laryngoscope (2005) 0.87
Effects of high altitude hypoxia on left ventricular systolic time intervals in man. Br Heart J (1975) 0.86
Changes in transthoracic electrical impedance during submaximal treadmill exercise in patients with ischemic heart disease--A preliminary report. Am Heart J (1976) 0.85
On-line digital computer quantitated ST segment response to sub-maximal tread mill exercise. J Assoc Physicians India (1975) 0.85
Cancer chemopreventive activity of synthetic colorants used in foods, pharmaceuticals and cosmetic preparations. Cancer Lett (1998) 0.85
Transthoracic electrical impedance in cases of high-altitude hypoxia. Br Med J (1974) 0.84
A distributed model of carbohydrate transport and metabolism in the liver during rest and high-intensity exercise. Ann Biomed Eng (2006) 0.84
Significance of tall precordial T waves: an electrocardiographic study in Indians. Chest (1973) 0.84
Biochemical basis of heart function. X. Reduction in the Na+-K+-stimulated ATPase activity in failing rat heart due to hypoxia. Can J Physiol Pharmacol (1973) 0.84
Counting probability distributions: differential geometry and model selection. Proc Natl Acad Sci U S A (2000) 0.83
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents. J Med Chem (2014) 0.83
Trace element profiles in single strands of human hair determined by HR-ICP-MS. Biol Trace Elem Res (2008) 0.82
4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity. J Med Chem (2014) 0.82
Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus early antigen activation by natural colorants. Cancer Lett (1997) 0.82
Uptake and efflux of methylmercury in vitro: comparison of transport mechanisms in C6, B35 and RBE4 cells. Toxicol In Vitro (2009) 0.82
Anti-tumor promoting effects of naphthoquinone derivatives on short term Epstein-Barr early antigen activation assay and in mouse skin carcinogenesis. Cancer Lett (1997) 0.82
The protective and allergenic potency of four BCG substrains in use in China determined in two animal models. Tubercle (1988) 0.81
Changes in transthoracic electrical impedance at high altitude. Br Heart J (1977) 0.80
Tenderness variation among loin steaks from A and C maturity carcasses of heifers similar in chronological age. J Anim Sci (1997) 0.80
Continuous recording of intra-arterial blood pressure during graded bicycle ergometry and stair climbing in essential hypertension. Biotelem Patient Monit (1981) 0.80
Platelet adhesiveness in permanent residents of high altitude. Thromb Haemost (1980) 0.80
Oxidative stress and tumor markers in cervical cancer patients. J Biochem Mol Biol Biophys (2002) 0.80
LDH isoenzyme studies in brain tumours. Indian J Cancer (1981) 0.80
Physical activity and the circadian rhythm of blood pressure. Clin Sci (Lond) (1979) 0.80
Biochemical basis of heart function. V. Effect of starvation on storage, transport, and synthesis of cardiac norepinephrine in rats. Can J Physiol Pharmacol (1972) 0.80
C-Peptide responses to glucose load in maturity-onset diabetes of the young (MODY). Diabetes Care (1985) 0.80
Effect of labetalol in hypertension during exercise and postural changes. Br J Clin Pharmacol (1979) 0.79
Aerosol infection model of tuberculosis in wistar rats. Int J Microbiol (2010) 0.79
Pancreatic beta-cell function in tropical pancreatic diabetes. Metabolism (1983) 0.79
Role of pinaverium bromide in south Indian patients with irritable bowel syndrome. J Assoc Physicians India (1998) 0.78
Serial studies of heart rate, blood pressure and urinary catecholamine excretion on acute induction to high altitude (3658m). Indian J Chest Dis Allied Sci (1977) 0.78
Irreversible inactivation of mammalian delta 5-3 beta-hydroxysteroid dehydrogenases by 5,10-secosteroids. Enzymatic oxidation of allenic alcohols to the corresponding allenic ketones. Biochem Biophys Res Commun (1981) 0.78
4-Ethenylidene steroids as mechanism-based inactivators of 3 beta-hydroxysteroid dehydrogenases. Steroids (1982) 0.78
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B. J Med Chem (2013) 0.78
Comparison of polyethylene glycol versus combination of magnesium sulphate and bisacodyl for colon preparation. Trop Gastroenterol (2000) 0.78
Development and characterization of a whole-cell radioligand binding assay for [125I]gp120 of HIV-1. J Immunoassay (1992) 0.77
Acid phosphatase production by recombinant Arxula adeninivorans. Appl Microbiol Biotechnol (2007) 0.77
Molecular cloning and characterization of a 3-hydroxy-3-methylglutaryl-coenzyme A reductase 1 (hmgr1) gene from rubber tree (Hevea brasiliensis Muell. Arg.): A key gene involved in isoprenoid biosynthesis. Physiol Mol Biol Plants (2009) 0.77
Effect of high-altitude exposure for 10 days on stroke volume and cardiac output. J Appl Physiol Respir Environ Exerc Physiol (1977) 0.77
Urinary catecholamine excretion on induction to high altitude (3,658 m) by air and road. J Appl Physiol Respir Environ Exerc Physiol (1977) 0.77
A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening. Pharm Res (2000) 0.77
Bilateral papillitis with anti-neutrophil cytoplasmic antibodies associated with coeliac disease. Postgrad Med J (1991) 0.77
Arteriovenous malformations with a purely external carotid contribution. J Neurosurg (1966) 0.77
Effect of submaximal exercise on fibrinolytic activity in ischaemic heart disease. Br Heart J (1975) 0.77